The treatment of acute myeloid leukemia (AML) has been rapidly evolved from conventional chemotherapy to target therapeutics such as FLT3-ITD and IDH2 inhibitors, thereby improving the complete remission rates over the past decade [1,2]. This evidence concerns the gene FLT3 and acute myeloid leukemia.